MCID: TNG003
MIFTS: 62

Tongue Cancer

Categories: Cancer diseases, Gastrointestinal diseases, Oral diseases, Rare diseases

Aliases & Classifications for Tongue Cancer

MalaCards integrated aliases for Tongue Cancer:

Name: Tongue Cancer 12 54 56 15
Tongue Carcinoma 54 56 74
Malignant Neoplasm of Tongue 12 74
Tongue Neoplasms 45 74
Malignant Neoplasm of Tip and/or Lateral Border of Tongue 12
Malignant Neoplasm of Tip and Lateral Border of Tongue 12
Malignant Neoplasm of Tongue, Tip and Lateral Border 12
Malignant Neoplasm of Anterior Two-Thirds of Tongue 12
Malignant Tumor of Anterior Two-Thirds of Tongue 12
Malignant Neoplasm of Junctional Zone of Tongue 12
Malignant Neoplasm of Ventral Surface of Tongue 12
Malignant Neoplasm of Dorsal Surface of Tongue 12
Malignant Neoplasm of Anterior 2/3 of Tongue 12
Malignant Neoplasm of Ventral Tongue Surface 12
Malignant Neoplasm of Mobile Part of Tongue 12
Malignant Neoplasm of Other Sites of Tongue 12
Malignant Neoplasm of Fixed Part of Tongue 12
Malignant Tumor of Mobile Part of Tongue 12
Malignant Neoplasm of Border of Tongue 12
Malignant Neoplasm of Dorsum of Tongue 12
Malignant Neoplasm of Base of Tongue 12
Malignant Neoplasm of Lingual Tonsil 12
Malignant Neoplasm of Dorsal Tongue 12
Malignant Tumor of Posterior Tongue 12
Malignant Tumor of Base of Tongue 12
Malignant Tumor of Lingual Tonsil 12
Malignant Tumor of Tongue 12
Tongue Neoplasm Malignant 12
Tongue Neoplasm 17

Classifications:



Summaries for Tongue Cancer

MalaCards based summary : Tongue Cancer, also known as tongue carcinoma, is related to tonsil cancer and periodontitis, and has symptoms including glossalgia An important gene associated with Tongue Cancer is MALAT1 (Metastasis Associated Lung Adenocarcinoma Transcript 1), and among its related pathways/superpathways are ERK Signaling and GPCR Pathway. The drugs Nicotine and Liver Extracts have been mentioned in the context of this disorder. Affiliated tissues include tongue, tonsil and lymph node, and related phenotypes are cardiovascular system and homeostasis/metabolism

Related Diseases for Tongue Cancer

Diseases related to Tongue Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 195)
# Related Disease Score Top Affiliating Genes
1 tonsil cancer 30.2 CDH1 CDKN2A TP53
2 periodontitis 29.9 MMP2 MMP8 MMP9
3 verrucous carcinoma 29.6 CCND1 CDKN2A TP53
4 oropharynx cancer 29.5 CCND1 CDH1 CDKN2A TP53
5 lynch syndrome 29.4 CCND1 CDKN2A CTNNB1 TP53
6 retinoblastoma 29.2 CCND1 CDKN1A CDKN2A MALAT1 TP53
7 papilloma 29.1 CCND1 CDKN1A CDKN2A KRT13 TP53
8 squamous cell carcinoma 28.5 BCYRN1 CCND1 CDH1 CDKN2A CTNNB1 MALAT1
9 oral cancer 28.5 CASP3 CCND1 CDH1 CDKN2A KRT13 MMP2
10 nasopharyngeal carcinoma 27.9 CASP3 CCND1 CDH1 CDKN2A KRT13 MALAT1
11 tongue squamous cell carcinoma 27.8 BMI1 CASP3 CDH1 CDH2 CDKN2A CTNNB1
12 colorectal cancer 27.0 BCYRN1 CASP3 CCND1 CDH1 CDKN1A CDKN2A
13 lung cancer 27.0 BCYRN1 CASP3 CCND1 CDH1 CDKN1A CDKN2A
14 esophageal cancer 26.9 BCYRN1 BMI1 CASP3 CCND1 CDH1 CDKN1A
15 breast cancer 26.5 BCYRN1 CASP3 CCND1 CDH1 CDH2 CDKN1A
16 adult hepatocellular carcinoma 10.4 CTNNB1 TP53
17 cerebral convexity meningioma 10.4 CDH1 TP53
18 extracranial arteriovenous malformation 10.4 MMP2 MMP9
19 actinic cheilitis 10.4 CDKN1A TP53
20 focal myositis 10.4 MMP2 MMP9
21 vulvar intraepithelial neoplasia 10.4 MMP2 TP53
22 invasive bladder transitional cell carcinoma 10.4 CDKN1A NOTCH1 TP53
23 villous adenocarcinoma 10.4 MMP2 MMP9
24 ovarian cancer 1 10.4 CDH1 MMP2 TP53
25 malignant ovarian surface epithelial-stromal neoplasm 10.4 CDH1 MMP2 TP53
26 ovary epithelial cancer 10.4 CDH1 MMP2 TP53
27 spastic entropion 10.3 MMP2 MMP9
28 lobular neoplasia 10.3 CDH1 CTNNB1 PRLR
29 splenic diffuse red pulp small b-cell lymphoma 10.3 NOTCH1 TP53
30 lentigo maligna melanoma 10.3 MMP2 MMP9
31 large intestine adenocarcinoma 10.3 CDH1 CTNNB1
32 colorectal adenocarcinoma 10.3 CDH1 CTNNB1 TP53
33 embryonal sarcoma 10.3 CTNNB1 MALAT1 TP53
34 intrahepatic cholangiocarcinoma 10.3 CDH1 CTNNB1 TP53
35 short-rib thoracic dysplasia 4 with or without polydactyly 10.3 CASP3 TP53
36 psammomatous meningioma 10.3 CTNNB1 MMP2 MMP9
37 transitional cell carcinoma 10.3 CDH1 CDKN2A TP53
38 uterine carcinosarcoma 10.3 CDH1 CTNNB1 TP53
39 suppressor of tumorigenicity 3 10.3 CDKN1A CDKN2A TP53
40 amaurosis fugax 10.3 MMP8 MMP9
41 ureteral obstruction 10.3 CTNNB1 TP53 VEGFC
42 adenomyosis 10.3 CDH1 MMP2 MMP9
43 in situ carcinoma 10.3 CDH1 CDKN2A TP53
44 klatskin's tumor 10.3 MALAT1 MMP2 MMP9
45 cervical adenocarcinoma 10.3 CDKN1A CDKN2A TP53
46 cholecystitis 10.3 CDH1 CDKN2A TP53
47 actinic keratosis 10.3 CDKN2A MMP2 TP53
48 vulva squamous cell carcinoma 10.3 CDKN2A MALAT1 TP53
49 epstein-barr virus-associated gastric carcinoma 10.2 CDH1 CDKN2A CTNNB1
50 gliosarcoma 10.2 MMP2 MMP9 TP53

Comorbidity relations with Tongue Cancer via Phenotypic Disease Network (PDN):


Protein-Energy Malnutrition Swallowing Disorders

Graphical network of the top 20 diseases related to Tongue Cancer:



Diseases related to Tongue Cancer

Symptoms & Phenotypes for Tongue Cancer

UMLS symptoms related to Tongue Cancer:


glossalgia

MGI Mouse Phenotypes related to Tongue Cancer:

47 (show all 18)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.35 CASP3 CCND1 CDH1 CDH2 CDKN1A CDKN2A
2 homeostasis/metabolism MP:0005376 10.34 CASP3 CCND1 CDH1 CDH2 CDKN1A CDKN2A
3 cellular MP:0005384 10.31 CASP3 CCND1 CDH1 CDH2 CDKN1A CDKN2A
4 growth/size/body region MP:0005378 10.29 CASP3 CCND1 CDH1 CDH2 CDKN1A CDKN2A
5 immune system MP:0005387 10.26 CASP3 CCND1 CDH1 CDKN1A CDKN2A CTNNB1
6 digestive/alimentary MP:0005381 10.2 CASP3 CCND1 CDH1 CDKN1A CDKN2A CTNNB1
7 endocrine/exocrine gland MP:0005379 10.18 CASP3 CCND1 CDH1 CDKN1A CDKN2A CTNNB1
8 integument MP:0010771 10.16 CASP3 CCND1 CDH1 CDKN1A CDKN2A CTNNB1
9 embryo MP:0005380 10.14 CDH1 CDH2 CDKN1A CDKN2A CTNNB1 NOTCH1
10 neoplasm MP:0002006 10.14 CCND1 CDH1 CDKN1A CDKN2A CTNNB1 MMP2
11 nervous system MP:0003631 10.11 CASP3 CCND1 CDH2 CDKN1A CDKN2A CTNNB1
12 craniofacial MP:0005382 10.1 CASP3 CCND1 CDKN1A CTNNB1 MMP2 NOTCH1
13 muscle MP:0005369 10.09 CASP3 CDH2 CDKN1A CDKN2A CTNNB1 MMP2
14 reproductive system MP:0005389 9.91 CASP3 CCND1 CDH1 CDKN1A CDKN2A CTNNB1
15 respiratory system MP:0005388 9.81 CASP3 CCND1 CDKN1A CDKN2A CTNNB1 MMP2
16 pigmentation MP:0001186 9.72 CASP3 CDKN2A CTNNB1 NOTCH1 TP53
17 skeleton MP:0005390 9.65 CASP3 CCND1 CDKN1A CDKN2A CTNNB1 MMP2
18 vision/eye MP:0005391 9.32 CASP3 CCND1 CDKN1A CDKN2A CTNNB1 MMP2

Drugs & Therapeutics for Tongue Cancer

Drugs for Tongue Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 152)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Nicotine Approved Phase 4,Not Applicable 54-11-5 89594 942
2 Liver Extracts Phase 4,Phase 2,Phase 1,Early Phase 1
3 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Not Applicable
4 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Not Applicable
5 Central Nervous System Stimulants Phase 4,Not Applicable
6 Autonomic Agents Phase 4,Phase 2,Phase 3,Not Applicable
7 Nicotinic Agonists Phase 4,Not Applicable
8 Cholinergic Agents Phase 4,Phase 2,Phase 3,Not Applicable
9
Aldesleukin Approved Phase 3 110942-02-4, 85898-30-2
10
Cisplatin Approved Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 15663-27-1 2767 441203 84093
11
Cetuximab Approved Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 205923-56-4 56842117 2333
12
Docetaxel Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1 114977-28-5 148124
13
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 38904 498142
14
Fluorouracil Approved Phase 3,Phase 2,Phase 1 51-21-8 3385
15
Histamine Approved, Investigational Phase 3 51-45-6 774
16
Doxepin Approved, Investigational Phase 3 1668-19-5 667468 667477
17
Diphenhydramine Approved, Investigational Phase 3 147-24-0, 58-73-1 3100
18
Promethazine Approved, Investigational Phase 3 60-87-7 4927
19
Pilocarpine Approved, Investigational Phase 2, Phase 3 54-71-7, 92-13-7 5910
20
Bevacizumab Approved, Investigational Phase 3,Phase 2 216974-75-3
21 Antiviral Agents Phase 3,Phase 2,Not Applicable
22 Anti-HIV Agents Phase 3,Phase 2
23 Anti-Retroviral Agents Phase 3,Phase 2
24 Anti-Infective Agents Phase 3,Phase 2,Phase 1,Not Applicable
25 Interleukin-2 Phase 3
26 Central Nervous System Depressants Phase 3,Not Applicable
27 Immunoglobulins Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable
28 Antimitotic Agents Phase 2, Phase 3,Phase 3,Phase 1
29 Antibodies, Monoclonal Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable
30 Antibodies Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable
31 Antineoplastic Agents, Immunological Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable
32 Immunologic Factors Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable,Early Phase 1
33 Antimetabolites Phase 3,Phase 2,Phase 1,Not Applicable
34 Angiogenesis Modulating Agents Phase 3,Phase 2,Phase 1
35 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
36 Immunosuppressive Agents Phase 3,Phase 2,Phase 1,Early Phase 1
37 Angiogenesis Inhibitors Phase 3,Phase 2,Phase 1
38 Histamine Antagonists Phase 3
39 Psychotropic Drugs Phase 3
40 Antidepressive Agents, Tricyclic Phase 3
41 Antidepressive Agents Phase 3
42
Histamine Phosphate Phase 3 51-74-1 65513
43 Hypnotics and Sedatives Phase 3
44 Muscarinic Agonists Phase 2, Phase 3
45 Vaccines Phase 3,Phase 1
46 Mitogens Phase 3,Phase 1,Phase 2
47 Immunoglobulin G Phase 3
48 Endothelial Growth Factors Phase 3
49
Paclitaxel Approved, Vet_approved Phase 2,Phase 1 33069-62-4 36314
50
Indinavir Approved Phase 2 150378-17-9 5362440

Interventional clinical trials:

(show top 50) (show all 107)
# Name Status NCT ID Phase Drugs
1 Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking Completed NCT00365508 Phase 4 nicotine lozenge;nicotine patch
2 PET/CT Scan-Guided Watchful Waiting or Neck Dissection of Locally Advanced Lymph Node Metastases in Treating Patients Undergoing Chemotherapy and Radiation Therapy for Primary Head And Neck Cancer Unknown status NCT00720070 Phase 3
3 Surgery and Radiation Therapy With or Without Interleukin-2 in Treating Patients With Cancer of the Mouth or Oropharynx Unknown status NCT00002702 Phase 3
4 Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy Completed NCT01156142 Phase 3 doxepin hydrochloride
5 Study of Nutrition Regimens in Treating Patients With Cancer of the Upper Aerodigestive Tract Completed NCT00765440 Phase 3
6 Acupuncture-Like Transcutaneous Electrical Nerve Stimulation (ALTENS) or Pilocarpine in Treating Early Dry Mouth in Patients Undergoing Radiation Therapy for Head and Neck Cancer Completed NCT00656513 Phase 2, Phase 3 Pilocarpine
7 Phase II Trial of Allovectin-7® for Head and Neck Cancer Completed NCT00050388 Phase 3
8 Radiation Therapy With Cisplatin, Docetaxel, or Cetuximab After Surgery in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer Active, not recruiting NCT01810913 Phase 2, Phase 3 cisplatin;docetaxel
9 Radiation Therapy With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer Active, not recruiting NCT00956007 Phase 3
10 Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Active, not recruiting NCT00588770 Phase 3 Carboplatin;Cisplatin;Docetaxel;Fluorouracil
11 Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients Who Have Undergone Surgery for Advanced Hypopharyngeal Cancer, Oropharyngeal Cancer, Laryngeal Cancer, or Oral Cavity Cancer at High Risk of Recurrence Withdrawn NCT01142414 Phase 3 cisplatin;fluorouracil
12 CETUXIMAB Given for 3 Weeks as Neoadjuvant Treatment in Locally Advanced Tongue Cancer ; A NEW PARADIGM OF TREATMENT Unknown status NCT01760811 Phase 1, Phase 2 Erbitux,merck serono
13 Neoadjuvant Chemotherapy for Locally Advanced Squamous Cell Cancer of the Head and Neck (SCCHN) Unknown status NCT01312350 Phase 2 neoadjuvant docetaxel/cisplatin/fluorouracil;No treatment before definitive CCRT
14 Trial of E10A in Head and Neck Cancer Unknown status NCT00634595 Phase 2 E10A;Cisplatin;Paclitaxel
15 PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Unknown status NCT01816984 Phase 1, Phase 2 PI3K inhibitor BKM120
16 External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
17 Docetaxel and S-1 Followed By Radiation Therapy and Low-Dose Cisplatin in Treating Patients With Stage III or Stage IV Head and Neck Cancer Unknown status NCT00625937 Phase 2 cisplatin;docetaxel;tegafur-gimeracil-oteracil potassium
18 Cetuximab and Combination Chemotherapy in Treating Patients With Stage III or Stage IV Oropharynx Cancer That Can Be Removed by Surgery Completed NCT00665392 Phase 2 cisplatin;docetaxel;fluorouracil;Cetuximab
19 Bowman-Birk Inhibitor Concentrate in Preventing Cancer in Patients With Oral Leukoplakia Completed NCT00330382 Phase 2 Bowman-Birk inhibitor concentrate
20 Induction Chemotherapy Followed By Cetuximab and Radiation in HPV-Associated Resectable Stage III/IV Oropharynx Cancer Completed NCT01084083 Phase 2 Paclitaxel;Cisplatin
21 Gene Therapy in Preventing Cancer in Patients With Premalignant Carcinoma of the Oral Cavity or Pharynx Completed NCT00064103 Phase 1, Phase 2
22 Acetylcysteine Rinse in Reducing Saliva Thickness and Mucositis in Patients With Head and Neck Cancer Undergoing Radiation Therapy Completed NCT02123511 Phase 2 acetylcysteine
23 Phase 1b Food Based Modulation of Biomarkers in Human Tissues at High-Risk for Oral Cancer. Completed NCT01469429 Phase 1, Phase 2 chemoprevention;chemoprevention
24 Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell Cancer Completed NCT01316757 Phase 2 paclitaxel;carboplatin;erlotinib hydrochloride
25 Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab Completed NCT00939627 Phase 2 sorafenib tosylate
26 Saracatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Completed NCT00513435 Phase 2 saracatinib
27 Dasatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Completed NCT00507767 Phase 2 dasatinib
28 Lapatinib Ditosylate in Treating Patients With Metastatic or Recurrent Head and Neck Cancer Completed NCT00114283 Phase 2 lapatinib ditosylate
29 Bortezomib With or Without Irinotecan in Treating Patients With Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Completed NCT00103259 Phase 2 bortezomib;irinotecan hydrochloride
30 S0420, Sorafenib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Completed NCT00096512 Phase 2 sorafenib tosylate
31 Ixabepilone in Treating Patients With Metastatic or Recurrent Squamous Cell Cancer of the Head and Neck Completed NCT00033618 Phase 2 ixabepilone
32 Celecoxib in Preventing Head and Neck Cancer in Patients With Oral Leukoplakia Completed NCT00101335 Phase 2 celecoxib
33 Soy Isoflavones in Preventing Head and Neck Cancer Recurrence in Patients With Stage I-IV Head and Neck Cancer Undergoing Surgery Completed NCT02007200 Phase 2 Soy Isoflavones
34 Temsirolimus With or Without Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer Who Did Not Respond to Previous Therapy Completed NCT01256385 Phase 2 Temsirolimus
35 Vorinostat in Treating Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic Carcinoma Completed NCT01175980 Phase 2 Vorinostat
36 Everolimus, Carboplatin, and Paclitaxel in Locally Advanced Head and Neck Cancer That Cannot Be Removed by Surgery Completed NCT01333085 Phase 1, Phase 2 carboplatin;RAD001;paclitaxel
37 Rapamycin Therapy in Head and Neck Squamous Cell Carcinoma Completed NCT01195922 Phase 1, Phase 2 Sirolimus
38 Chemotherapy, Radiation Therapy, and Cetuximab in Treating Patients With the Head and Neck Cancer Completed NCT00875849 Phase 2 cisplatin
39 Nab-Paclitaxel, Cisplatin, and Cetuximab With Concurrent Radiation Therapy for Locally Advanced Head and Neck Cancer Completed NCT00851877 Phase 1, Phase 2 Cisplatin;Nab-Paclitaxel
40 Cetuximab, Cisplatin, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer Completed NCT00833261 Phase 2 cetuximab;cisplatin
41 Cediranib Maleate in Treating Patients With Recurrent or Newly Diagnosed Metastatic Head and Neck Cancer Completed NCT00458978 Phase 2 Cediranib Maleate
42 Cisplatin, Bevacizumab, and Intensity-Modulated Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer Completed NCT00423930 Phase 2 cisplatin
43 Zinc Supplements in Lowering Cadmium Levels in Smokers Completed NCT00376987 Phase 2
44 Correlation of FAZA PET Hypoxia Imaging To 3D Histology in Oral Tongue Cancer Recruiting NCT03181035 Phase 1, Phase 2 Pimonidazole
45 High-activity Natural Killer Immunotherapy for Small Metastases of Tongue Cancer Recruiting NCT03008330 Phase 1, Phase 2
46 Combination of Cryosurgey and NK Immunotherapy for Recurrent Tongue Cancer Recruiting NCT02849379 Phase 1, Phase 2
47 A Dye for the Detection of Cancer of the Tongue and Mouth Recruiting NCT03085147 Phase 1, Phase 2 Olaparib
48 Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene Recruiting NCT03602079 Phase 1, Phase 2 A166
49 Effect of COX-2 and EGFR Suppression on Molecular Markers of Angiogenesis and Proliferation in Squamous Cell Carcinoma of Oral Cavity - Prospective Randomized Study Active, not recruiting NCT02748707 Phase 2 Arm1;Arm 2;Arm 3
50 Reduced-Dose Intensity-Modulated Radiation Therapy With or Without Cisplatin in Treating Patients With Advanced Oropharyngeal Cancer Active, not recruiting NCT02254278 Phase 2 Cisplatin

Search NIH Clinical Center for Tongue Cancer

Cochrane evidence based reviews: tongue neoplasms

Genetic Tests for Tongue Cancer

Anatomical Context for Tongue Cancer

MalaCards organs/tissues related to Tongue Cancer:

42
Tongue, Tonsil, Lymph Node, Brain, Endothelial, Colon, B Cells

Publications for Tongue Cancer

Articles related to Tongue Cancer:

(show top 50) (show all 801)
# Title Authors Year
1
Oral tongue cancer in a patient with hereditary nonpolyposis colorectal cancer: A case report and review of the literature. ( 30885722 )
2019
2
Stage II Oral Tongue Cancer: Survival Impact of Adjuvant Radiation Based on Depth of Invasion. ( 29944460 )
2019
3
Profiling and bioinformatics analyses reveal differential expression of circular RNA in tongue cancer revealed by high-throughput sequencing. ( 30269358 )
2019
4
Sentinel lymph node biopsy for early stage tongue cancer-a 14-year single-centre experience. ( 30389112 )
2019
5
CCR4 Expression Is Associated With Poor Prognosis in Patients With Early Stage (pN0) Oral Tongue Cancer. ( 30395826 )
2019
6
Clinical features and outcomes in young adults with oral tongue cancer. ( 30472130 )
2019
7
Prognostic performance of the American Joint Committee on Cancer 8th edition of the TNM staging system in patients with early oral tongue cancer. ( 30537405 )
2019
8
Prognostic Significance of Pretreatment Lymphocyte-to-Monocyte Ratio in Patients with Tongue Cancer. ( 30591487 )
2019
9
Classification of GLOSSECTOMIES: Proposal for tongue cancer resections. ( 30600861 )
2019
10
Undetectability of oral tongue cancer on magnetic resonance imaging; clinical significance as a predictor to avoid unnecessary elective neck dissection in node negative patients. ( 30608183 )
2019
11
A Feedback Loop between MicroRNA 155 (miR-155), Programmed Cell Death 4, and Activation Protein 1 Modulates the Expression of miR-155 and Tumorigenesis in Tongue Cancer. ( 30617160 )
2019
12
LncRNA UCA1/miR-124 axis modulates TGFβ1-induced epithelial-mesenchymal transition and invasion of tongue cancer cells through JAG1/Notch signaling. ( 30635938 )
2019
13
Evodiamine inactivates NF-κB and potentiates the antitumor effects of gemcitabine on tongue cancer both in vitro and in vivo. ( 30643424 )
2019
14
Sirtuin 3 inhibition induces mitochondrial stress in tongue cancer by targeting mitochondrial fission and the JNK-Fis1 biological axis. ( 30656603 )
2019
15
Kinesin family member 20B regulates tongue cancer progression by promoting cell proliferation. ( 30664160 )
2019
16
Controversies in relation to neck management in N0 early oral tongue cancer. ( 30668761 )
2019
17
MG53 Inhibits the Progression of Tongue Cancer Cells through Regulating PI3K-AKT Signaling Pathway: Evidence from 3D Cell Culture and Animal Model. ( 30690890 )
2019
18
The 8th Edition of the American Joint Committee on Cancer (AJCC8) Staging Manual: any improvement in the prognostication of oral tongue cancer? ( 30691272 )
2019
19
Invasive Candida tropicalis Infection Caused by Catheter Biofilm in a Patient with Tongue Cancer. ( 30707339 )
2019
20
Superior Vena Cava Cancerous Thrombus Due to Squamous Cell Tongue Cancer: Virchow's Triad at Its Worst Version. ( 30743273 )
2019
21
A National Cancer Database Analysis of the effect of brachytherapy on overall survival in patients with base of tongue cancer. ( 30788877 )
2019
22
Comparison of the subjective satisfaction of the donor site morbidity: Free radial forearm flap versus anterolateral thigh flap for reconstruction in tongue cancer patients. ( 30818317 )
2019
23
A Proposal to Revise the Histopathologic Grading System of Early Oral Tongue Cancer Incorporating Tumor Budding. ( 30829728 )
2019
24
MRI prognostic factors of tongue cancer: potential predictors of cervical lymph nodes metastases. ( 30840589 )
2019
25
Preventive Effect of Lactobacillus fermentum CQPC08 on 4-Nitroquineline-1-Oxide Induced Tongue Cancer in C57BL/6 Mice. ( 30861992 )
2019
26
Long-term disease-free survival in surgically-resected oral tongue cancer: a 10-year retrospective study. ( 31097825 )
2019
27
Interleukin-17F Has Anti-Tumor Effects in Oral Tongue Cancer. ( 31083515 )
2019
28
The effect of depth of invasion on node negative tongue cancer staging. ( 31046152 )
2019
29
Recategorization of tumor stage in patients with node-negative oral tongue cancer: Impact of the eighth edition American Joint Committee staging system. ( 31025799 )
2019
30
Numb inhibits epithelial-mesenchymal transition via RBP-Jκ-dependent Notch1/PTEN/FAK signaling pathway in tongue cancer. ( 31023264 )
2019
31
The role of the T-N tract in advanced stage tongue cancer. ( 30942940 )
2019
32
Accuracy of magnetic resonance imaging in evaluating the depth of invasion of tongue cancer. A prospective cohort study. ( 30926067 )
2019
33
Is skip metastases associated with tumor thickness and tumor size in tongue carcinoma patients? ( 30238418 )
2019
34
Mutational signatures and the genomic landscape of betel quid chewing-associated tongue carcinoma. ( 30672146 )
2019
35
Evaluation of the budding and depth of invasion (BD) model in oral tongue cancer biopsies. ( 28766010 )
2018
36
Survival and recurrence of resectable tongue cancer: Resection margin cutoff value by T classification. ( 28960654 )
2018
37
Efficacy of postoperative neck irradiation for regional control in patients with pN0 oral tongue cancer: Propensity analysis. ( 29083541 )
2018
38
Notch1 regulates tongue cancer cells proliferation, apoptosis and invasion. ( 29117785 )
2018
39
Change in reimbursement and costs in German oncological head and neck surgery over the last decade: ablative tongue cancer surgery and reconstruction with split-thickness skin graft vs. microvascular radial forearm flap. ( 29124365 )
2018
40
Functional evaluation of swallowing in patients with tongue cancer before and after surgery using high-speed continuous magnetic resonance imaging based on T2-weighted sequences. ( 29128287 )
2018
41
Long noncoding RNA Lnc‑EGFR promotes cell proliferation and inhibits cell apoptosis via regulating the expression of EGFR in human tongue cancer. ( 29138845 )
2018
42
Cancer-associated fibroblasts confer cisplatin resistance of tongue cancer via autophagy activation. ( 29156523 )
2018
43
Intraoperative Ultrasound in Oral Tongue Cancer Resection: Feasibility Study and Early Outcomes. ( 29161194 )
2018
44
Distribution of cervical metastasis in tongue cancer: Are occult metastases predictable? A retrospective study of 117 oral tongue carcinomas. ( 29174473 )
2018
45
Survival and Functional Outcome after Treatment for Primary Base of Tongue Cancer: A Comparison of Definitive Chemoradiotherapy versus Surgery Followed by Adjuvant Radiotherapy. ( 29281874 )
2018
46
Effect of induction chemotherapy on the quality-of-life in patients with advanced stage tongue cancer by a prospective study. ( 29332408 )
2018
47
Angiogenesis and evading immune destruction are the main related transcriptomic characteristics to the invasive process of oral tongue cancer. ( 29386520 )
2018
48
Simple laryngeal suspension procedure by suturing the digastric muscle to the periosteum of the mandible in neck dissection for tongue cancer. ( 29395281 )
2018
49
Classification of tongue cancer resection and treatment algorithm. ( 29432642 )
2018
50
Effects of low-intensity ultrasound combined with low-dose carboplatin in an orthotopic hamster model of tongue cancer: A preclinical study. ( 29436690 )
2018

Variations for Tongue Cancer

Expression for Tongue Cancer

Search GEO for disease gene expression data for Tongue Cancer.

Pathways for Tongue Cancer

Pathways related to Tongue Cancer according to GeneCards Suite gene sharing:

(show top 50) (show all 72)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.9 CASP3 CCND1 CDH1 CDH2 CDKN1A CDKN2A
2
Show member pathways
13.76 CCND1 CDKN1A CDKN2A MMP2 MMP8 MMP9
3
Show member pathways
13.39 CASP3 CCND1 CDKN1A MMP2 MMP9 PRLR
4
Show member pathways
13 CASP3 CCND1 CDKN1A CDKN2A CTNNB1 MMP9
5
Show member pathways
12.96 CASP3 CCND1 CDKN1A CTNNB1 NOTCH1 PRLR
6
Show member pathways
12.82 CASP3 CCND1 CDH1 CDKN1A CDKN2A CTNNB1
7
Show member pathways
12.78 CASP3 CDH1 MMP2 MMP8 MMP9
8
Show member pathways
12.77 CCND1 CDH1 CDKN1A CDKN2A CTNNB1 NOTCH1
9
Show member pathways
12.6 CCND1 CDH1 CDKN1A CDKN2A MMP2 MMP9
10 12.47 CCND1 CDH1 CDH2 CTNNB1 TP53
11
Show member pathways
12.46 CASP3 CCND1 CDH1 CTNNB1 MMP2 MMP9
12
Show member pathways
12.41 CASP3 CCND1 CDKN1A CDKN2A TP53
13 12.4 CCND1 CDKN1A CDKN2A CTNNB1 TP53
14 12.4 CCND1 CDH1 CDKN1A CDKN2A TP53
15
Show member pathways
12.39 CCND1 CDKN1A CDKN2A TP53
16 12.33 BMI1 CASP3 CCND1 CDKN1A CDKN2A MMP9
17 12.32 CASP3 CCND1 CDKN1A CDKN2A TP53
18 12.29 BMI1 CDKN1A MMP9 TP53
19
Show member pathways
12.29 CASP3 CCND1 CDKN1A TP53
20
Show member pathways
12.23 CASP3 CCND1 CDKN1A TP53
21 12.21 CCND1 CDKN1A CDKN2A TP53
22 12.18 CASP3 CCND1 CDKN1A TP53
23 12.17 CASP3 CCND1 CDH1 CTNNB1 TP53
24 12.17 CASP3 CCND1 CDKN1A CTNNB1 MMP2 MMP9
25
Show member pathways
12.16 CCND1 CDKN1A CTNNB1 MMP2
26 12.13 CTNNB1 MMP2 MMP9 TP53
27 12.13 CASP3 CDH1 CDH2 CTNNB1 NOTCH1
28 12.09 CDKN1A CDKN2A CTNNB1 MMP2 TP53
29 12.09 CASP3 CCND1 CDH1 CDKN1A CDKN2A CTNNB1
30 12.06 CASP3 CCND1 MMP9 TP53
31 12.04 CDH1 CDH2 CTNNB1 MMP2 MMP9
32 12.03 CCND1 CTNNB1 NOTCH1 TP53
33
Show member pathways
12.02 CCND1 CDH1 CDH2 CTNNB1 TP53
34 11.99 BMI1 CDKN1A CDKN2A TP53
35 11.99 CCND1 CDKN1A CDKN2A CTNNB1 TP53
36 11.98 CASP3 CCND1 CDH1 CDKN1A CTNNB1 MMP2
37 11.97 CCND1 CDKN1A MMP2 MMP9 TP53
38 11.96 CDH1 CDH2 CTNNB1 NOTCH1
39 11.95 CASP3 CCND1 MMP2 VEGFC
40 11.94 CCND1 CDKN1A CDKN2A CTNNB1 TP53
41 11.91 CASP3 CCND1 CDKN1A TP53
42 11.88 CCND1 CDKN1A CTNNB1
43 11.88 MMP2 MMP9 NOTCH1 VEGFC
44 11.86 CCND1 CDKN1A TP53
45 11.82 BMI1 MMP9 TP53
46 11.79 CDH2 CDKN1A CTNNB1 NOTCH1
47 11.78 CASP3 CDKN1A CDKN2A TP53
48 11.75 CCND1 CDH1 CTNNB1 MMP2 MMP9
49 11.73 CDKN1A CDKN2A CTNNB1 MMP2 TP53
50 11.72 CASP3 MMP2 MMP9

GO Terms for Tongue Cancer

Cellular components related to Tongue Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 adherens junction GO:0005912 9.43 CDH2 CTNNB1 NOTCH1
2 fascia adherens GO:0005916 9.16 CDH2 CTNNB1
3 flotillin complex GO:0016600 8.96 CDH1 CTNNB1
4 catenin complex GO:0016342 8.8 CDH1 CDH2 CTNNB1

Biological processes related to Tongue Cancer according to GeneCards Suite gene sharing:

(show all 29)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.99 CDKN2A CTNNB1 MMP8 NOTCH1 TP53
2 negative regulation of apoptotic process GO:0043066 9.99 CASP3 CDKN1A CTNNB1 MMP9 PRLR TP53
3 G1/S transition of mitotic cell cycle GO:0000082 9.82 CCND1 CDKN1A CDKN2A
4 Ras protein signal transduction GO:0007265 9.8 CDKN1A CDKN2A TP53
5 cell cycle arrest GO:0007050 9.8 CDKN1A CDKN2A NOTCH1 TP53
6 response to glucocorticoid GO:0051384 9.79 CASP3 CCND1 CDKN1A
7 extracellular matrix disassembly GO:0022617 9.76 MMP2 MMP8 MMP9
8 positive regulation of apoptotic process GO:0043065 9.73 CASP3 CDKN2A CTNNB1 MMP9 NOTCH1 TP53
9 animal organ regeneration GO:0031100 9.72 CCND1 CDKN1A NOTCH1
10 adherens junction organization GO:0034332 9.71 CDH1 CDH2 CTNNB1
11 response to organic substance GO:0010033 9.71 CASP3 CCND1 CDH1 CDKN1A
12 embryo implantation GO:0007566 9.7 MMP2 MMP9 PRLR
13 collagen catabolic process GO:0030574 9.65 MMP2 MMP8 MMP9
14 morphogenesis of embryonic epithelium GO:0016331 9.64 CTNNB1 VEGFC
15 negative regulation of oligodendrocyte differentiation GO:0048715 9.63 CTNNB1 NOTCH1
16 somatic stem cell division GO:0048103 9.63 CDKN2A NOTCH1
17 endodermal cell differentiation GO:0035987 9.63 MMP2 MMP8 MMP9
18 entry of bacterium into host cell GO:0035635 9.61 CDH1 CTNNB1
19 negative regulation of cyclin-dependent protein serine/threonine kinase activity GO:0045736 9.61 CASP3 CDKN1A CDKN2A
20 mitotic G1 DNA damage checkpoint GO:0031571 9.6 CCND1 TP53
21 cellular response to indole-3-methanol GO:0071681 9.58 CDH1 CTNNB1
22 regulation of neuroinflammatory response GO:0150077 9.57 MMP8 MMP9
23 signal transduction by p53 class mediator GO:0072331 9.56 CDKN1A TP53
24 positive regulation of neuroblast proliferation GO:0002052 9.54 CTNNB1 NOTCH1 VEGFC
25 response to X-ray GO:0010165 9.5 CASP3 CCND1 CDKN1A
26 response to drug GO:0042493 9.43 CASP3 CCND1 CDH1 CDKN1A CTNNB1 VEGFC
27 replicative senescence GO:0090399 9.33 CDKN1A CDKN2A TP53
28 cytokine-mediated signaling pathway GO:0019221 9.1 CASP3 CCND1 CDKN1A MMP2 MMP9 TP53
29 negative regulation of cell proliferation GO:0008285 10.01 CDKN1A CDKN2A CTNNB1 NOTCH1 TP53

Molecular functions related to Tongue Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 enzyme binding GO:0019899 9.65 CCND1 CDH2 CTNNB1 NOTCH1 TP53
2 protein phosphatase binding GO:0019903 9.54 CDH2 CTNNB1 TP53
3 protein kinase binding GO:0019901 9.43 CCND1 CDH2 CDKN1A CDKN2A CTNNB1 TP53
4 gamma-catenin binding GO:0045295 9.4 CDH1 CDH2
5 disordered domain specific binding GO:0097718 9.33 CDKN2A CTNNB1 TP53
6 alpha-catenin binding GO:0045294 9.32 CDH2 CTNNB1
7 cyclin-dependent protein serine/threonine kinase inhibitor activity GO:0004861 8.8 CASP3 CDKN1A CDKN2A

Sources for Tongue Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....